Clinical Roundup Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial April 12, 2024Vol.50 No.15
Clinical Roundup Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data April 12, 2024Vol.50 No.15
Clinical Roundup Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows April 12, 2024Vol.50 No.15
Drugs & Targets FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors April 12, 2024Vol.50 No.15
Drugs & Targets EC expands approval of Reblozyl to first-line treatment of anemia in MDS April 12, 2024Vol.50 No.15
Conversation with The Cancer Letter OHSU Knight Cancer Institute splits leadership role in two: (1) CEO and (2) center directorEight NCI-designated centers believe the top job is too big for one person April 05, 2024Vol.50 No.14By Paul Goldberg
NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24 April 05, 2024Vol.50 No.14By Matthew Bin Han Ong
White House White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups April 05, 2024Vol.50 No.14By Jacquelyn Cobb
Trials & Tribulations A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms April 05, 2024Vol.50 No.14By Jennifer A. Steel
In Brief Pfizer’s Albert Bourla to receive the AACR Outstanding Achievement Award for Service to Cancer Science and Medicine April 05, 2024Vol.50 No.14
